Clinical Trials
35 trialsMORPHEUS HR+BC
Hoffmann-La Roche
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Syndax Pharmaceuticals
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Syndax Pharmaceuticals
NA_00084192
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
UNC Lineberger Comprehensive Cancer Center
PEMDAC
Vastra Gotaland Region
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Breast49
University of Virginia
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
Syndax Pharmaceuticals
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
Syndax Pharmaceuticals
Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Kyowa Kirin Co., Ltd.
ENCORE301
Syndax Pharmaceuticals
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
Syndax Pharmaceuticals
ENCORE110
Syndax Pharmaceuticals
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
National Cancer Institute (NCI)
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
National Cancer Institute (NCI)
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Bayer
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
National Cancer Institute (NCI)
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
MS-275 in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins